Results 251 to 260 of about 9,194 (267)
Some of the next articles are maybe not open access.
Alphastrahler Radium-223-Dichlorid
Der Urologe, 2014Radium-223 dichloride (Ra-223) is an alpha emitter with low toxicity for the treatment of patients with castrations-resistant prostate cancer (CRPC) and symptomatic bone metastases showing a 30% reduction in the risk of death, as compared to placebo. Because of the favorable physical and chemical characteristics, Ra-223 can be handled easily in daily ...
H. Heinzer, F. König, S. Klutmann
openaire +1 more source
Bone-Targeting Radiopharmaceuticals Including Radium-223
The Cancer Journal, 2013Bone-seeking radionuclides including samarium-153 ethylene diamine tetramethylene phosphonate and strontium-89 have been used for decades in the palliation of pain from bone metastases especially from prostate cancer. Emerging evidence of improved survival in metastatic castration-resistant prostate cancer (CRPC) with the first-in-class α-radionuclide,
Brady, Darren +2 more
openaire +3 more sources
Journal of Inorganic and Nuclear Chemistry, 1965
Abstract The half-life of radium-223 has been determined simultaneously by microcalorimetry and proportional alpha counting, with 5 mc of radium-223 separated from actinium-227 and thorium-227 by cation exchange. A 4-mc fraction of the purified radium-223 was transferred to a tantalum capsule, dried, ignited at red heat, and hermetically sealed. The
H.W. Kirby +4 more
openaire +1 more source
Abstract The half-life of radium-223 has been determined simultaneously by microcalorimetry and proportional alpha counting, with 5 mc of radium-223 separated from actinium-227 and thorium-227 by cation exchange. A 4-mc fraction of the purified radium-223 was transferred to a tantalum capsule, dried, ignited at red heat, and hermetically sealed. The
H.W. Kirby +4 more
openaire +1 more source
Info Onkologie, 2014
Fur Patienten mit metastasiertem kastrationsresistentem Prostatakrebs (mCRPC) ist Radium-223 eine interessante Option.
openaire +1 more source
Fur Patienten mit metastasiertem kastrationsresistentem Prostatakrebs (mCRPC) ist Radium-223 eine interessante Option.
openaire +1 more source